-
Morepen Clocks Highest-Ever Quarterly Revenue and Earnings in Q1'FY27; EBITDA Grows by 207% and PAT by 394%; CDMO Enters Full Scale Commercialization
Gurugram, Haryana, India Morepen Laboratories Limited (NSE: MOREPENLAB; BSE: 500288) today announced its financial results for the quarter ended June 30, 2026, reporting its highest-ever quarterly revenue and highest-ever quarterly earnings, supported by better operating leverage, improved performance on API front, strong export growth and full scale commercialization of CDMO mandate. Morepen Q1FY27 Results Highlights…
-
Morepen Starts Commercial Supplies Under its Rs. 825 Crore CDMO Mandate; First Rs. 50 Crore Dispatch Already Completed in Q1FY2026-27
Gurugram, Haryana, India Morepen Laboratories Limited (NSE: MOREPENLAB; BSE: 500288) today issued an update on its recently announced Rs. 825 crore CDMO mandate. The first commercial dispatch, valued at approximately Rs. 50 crore, has already been completed by the company under the program during Q1FY2026-27. This marks the successful transition of the mandate from validation…
-
Morepen Bags Rs. 825 Crore Global Deal
Morepen Laboratories Limited (NSE: MOREPENLAB; BSE: 500288) has secured a multi-year Contract Development and Manufacturing Organization (CDMO) mandate valued at approximately Rs. 825 crore (USD 91 million) from a leading global pharma major. Morepen Bags Rs. 825 Crore Global Deal, Expands into High-Growth CDMO Segment Supplies under the mandate are expected to commence within the…
-
Morepen Labs' Facility Clears USFDA Inspection with NIL Adverse Observation for the Record Fourth Consecutive Time
Company sets a benchmark again in pharmaceutical excellence reinforcing its global leadership in quality and regulatory compliance Gurugram, Haryana, India Morepen Laboratories Limited (NSE: MOREPENLAB; BSE: 500288) has announced the successful completion of a USFDA (United States Food and Drug Administration) inspection at its Masulakhanna (Himachal) facility, with Zero adverse observations (No Form 483 issued…
-
Morepen Labs Q4 Net Profit Rises 69 percent; CDMO Program Moves into Commercial Execution; Board Proposes a Dividend of 10 percent for FY 2025-26
Gurugram, Haryana, India Morepen Laboratories Limited reported strong Q4 FY26 performance with net profit rising 69% YoY to Rs. 20 crore and gross revenue increasing 22% YoY to Rs. 472 crore. Revenue growth during the quarter was supported by export momentum and expansion in the Medical Devices business, while operational momentum strengthened toward the latter…
Latest News
About the Author
We increase the awareness of millions of users through our news networks. We are one of the most trusted news networks in the world.
